Study of plasma-derived plasminogen in patients with chronic tympanic membrane perforations

Trial Profile

Study of plasma-derived plasminogen in patients with chronic tympanic membrane perforations

Planning
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Plasminogen activator enzymes (Primary)
  • Indications Ear disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2016 New trial record
    • 06 Sep 2016 According to ProMetic media release, company expects to file its clinical trial application ("CTA") in Q4 2016.
    • 06 Sep 2016 According to ProMetic media release, company plans to initiate this study in H12017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top